Hormonal Contraceptives Global Market Report 2024

The hormonal contraceptives market size has grown steadily in recent years. It will grow from $13.96 billion in 2023 to $14.28 billion in 2024 at a compound annual growth rate (CAGR) of 2.3%. The growth observed in the historical period can be credited to government initiatives, a rise in contraceptive usage, increased expenditure on pharmaceutical research and development, augmented healthcare spending, and an expansion in the number of healthcare facilities.

The hormonal contraceptives market size is expected to see steady growth in the next few years. It will grow to $15.57 billion in 2028 at a compound annual growth rate (CAGR) of 2.2%. The anticipated growth in the forecast period can be ascribed to the rising awareness of family planning, heightened spending on research and development, an upswing in healthcare expenditure, and the escalating collaborations between agencies. Major trends expected in the forecast period encompass investments in longer-lasting vaginal rings, the adoption of AI solutions to enhance medication adherence, the introduction of innovative products, investments in environmentally friendly estrogen profiles, advancements in improved progestogen-only birth control pills, and a continued focus on investing in long-term drug delivery systems.

The heightened awareness surrounding hormonal contraceptives has empowered individuals to make well-informed decisions aligned with their reproductive goals and lifestyles. This increased awareness enables individuals to make choices that better suit their family planning and lifestyle preferences. In September 2023, the World Health Organization (WHO) reported that global contraception prevalence, including any method, reached 65% in 2022, with modern contraceptive methods at 58.7% among married women in a union. Additionally, the global demand for family planning among women increased from 900 million to nearly 1.1 billion in 2021, with a projected global satisfaction rate of 77.5% among women aged 15–49 in 2022. This elevated awareness significantly propels the hormonal contraceptives market.

The escalating rate of unplanned pregnancies is anticipated to drive the growth of the hormonal contraceptive market. Unplanned pregnancies, categorized as unwanted or unplanned, pose a significant global challenge. Hormonal contraceptives offer a reliable and convenient solution to prevent unplanned pregnancies, giving individuals and couples greater control over family planning. According to the United Nations Population Fund in March 2022, there were 121 million unintended pregnancies globally each year, with Afghanistan projected to experience 4.8 million unintended pregnancies in 2025. Thus, the increasing rate of unplanned pregnancies is expected to fuel the growth of the hormonal contraceptives market.

Companies are innovating by introducing chewable, low-dose oral contraceptives to reduce side effects and enhance daily regimen adherence. The availability of chewable contraceptives as an over-the-counter product aims to improve patient compliance and minimize side effects. Leading companies, such as Lupin Pharmaceuticals, Walter Chilcott, and Watson Pharmaceuticals, are actively participating in this initiative.

Major players in the hormonal contraceptives market are diversifying their product offerings by developing plant-based pills such as Nextellis, aiming to gain a competitive edge. Nextellis, a contraceptive pill containing a unique combination of 3 mg drospirenone (DRSP) and 14.2 mg estetrol (E4) tablets, presents a novel mechanism of action for pregnancy prevention. In April 2021, Mayne Pharma received FDA approval for Nextellis, making it the first contraceptive product to incorporate E4, a naturally occurring estrogen derived from plant sources. This distinct mechanism of action offers potential benefits compared to other estrogen-based contraceptives.

Major companies operating in the hormonal contraceptives market report are Bayer AG, Merck & Co. Inc., Viatris, Gedeon Richter, AbbVie Pfizer, Teva Pharmaceuticals, Mayne Pharma Group Limited, Lupin Limited, HLL Lifecare Limited, Amneal Pharmaceuticals, DKT International, Piramal Pharma Limited, Allergan, Afaxys Inc., Agile Therapeutic, Cipla Limited, Glenmark Pharmaceuticals, Novartis AG, Sun Pharmaceutical Industries Ltd., Apothecus Pharmaceutical Corporation, Amgen, Ansell Limited, Church & Dwight Co, Johnson & Johnson, Mayer Laboratories, Famy care, Mylan Laboratories


North America was the largest region in the hormonal contraceptives market share in 2023. Middle East is expected to be the fastest-growing region in the global hormonal contraceptives market analysis during the forecast period. The regions covered in the hormonal contraceptives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hormonal contraceptives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The hormonal contraceptive market includes revenues earned by entities by blocking the release of eggs from the ovaries and thinning the lining of the uterus to prevent pregnancy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.